Skip to main content
. 2024 Jul 22;41(9):3569–3584. doi: 10.1007/s12325-024-02938-2

Fig. 3.

Fig. 3

Potential solutions that reached a consensus (suitability), by subgroup. CV cardiovascular, CVD cardiovascular disease, GLP-1 RAs glucagon-like peptide 1 receptor agonists, N number of physicians, T2D type 2 diabetes